Development of a treatment algorithm for kinase inhibitor therapy in CML.

自从靶向治疗出现以来，慢性髓系白血病已经成为一种高度可治疗的疾病。现在有3种高效药物可供选择，伊马替尼、尼洛替尼和达沙替尼。我们正在开发药物敏感性分析，可以用来预测对这三种药物的反应。我们建议，这些检测方法可以用于个体化治疗，以确保从诊断开始就为每个患者提供最佳的药物，从而提供具有成本效益的个性化治疗方法。

Chronic myeloid leukaemia has become a highly treatable condition since targeted therapy became available. There are now 3 highly effective drugs available, imatinib, nilotinib and dasatinib. We are developing drug sensitivity assays that can be used to predict response to these 3 drugs. We propose that these assays could be used to individualise therapy to ensure that the optimal drug can be provided for each patient from diagnosis to provide a cost-effective customized approach to therapy.